HANXBIO-B (03378) announced that four of its innovative drug research findings have been selected for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The event is scheduled to take place from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. This selection further validates the company's research and development capabilities and innovation potential.
The first poster will feature HX044, a globally innovative CTLA-4/SIRPα bifunctional fusion protein. As a next-generation CTLA-4 targeted therapy, it works by simultaneously targeting CTLA-4 and CD47 to enhance the depletion of regulatory T-cells in the tumor microenvironment. This mechanism reduces immunosuppression against the tumor and boosts anti-tumor activity. Its primary development focus is for PD-1/ICI resistant solid tumors, and it forms a synergistic and complementary oncology immunotherapy pipeline with the company's HX009.
The second poster will present HX116, a potentially first-in-class bispecific antibody-drug conjugate (BsAbADC) developed in-house. It targets PD-(L)1 and VEGF and introduces additional mechanisms of action, such as direct killing and enhanced anti-tumor immunity through immunogenic cell death, thereby increasing anti-tumor activity. It is considered to have significant market potential. In preclinical studies, HX116 demonstrated superior activity compared to its parent BsAb.
The third poster will showcase HX112, a novel PD-L1 targeting ADC developed by the company, which is intended for the treatment of a broad range of solid tumors.
The fourth poster will present a study on the company's innovative 3D tumor organoid ADC evaluation system. This research validates that 3D tumor organoids are more predictive of a drug's in vivo anti-tumor effects compared to traditional 2D cell cultures.
Comments